NEW YORK (
) -- Drugmaker
said Monday a Phase III study of zibotentan monotherapy in patients with prostate cancer will be stopped since the drug is unlikely to meet its endpoints of progression free survival and overall survival.
"AstraZeneca felt it was prudent to take an early view on the progress of Study 15 following the announcement in September 2010 that ENTHUSE Study 14, evaluating zibotentan monotherapy, did not show a significant improvement in the primary endpoint of overall survival in patients with metastatic (castrate resistant prostate cancer)," the company said in a statement.
-- Written by Joseph Woelfel
>To contact the writer of this article, click here:
>To submit a news tip, send an email to: